Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · February 08, 2021

Perioperative Trastuzumab, Capecitabine, and Oxaliplatin in Patients With HER2+ Resectable Gastric or Gastro-Oesophageal Junction Adenocarcinoma

European Journal of Cancer


Additional Info

European Journal of Cancer
Perioperative Trastuzumab, Capecitabine and Oxaliplatin in Patients With HER2-Positive Resectable Gastric or Gastro-Oesophageal Junction Adenocarcinoma: NEOHX Phase II Trial
Eur. J. Cancer 2021 Mar 01;145(xx)158-167, F Rivera, M Izquierdo-Manuel, P García-Alfonso, E Martínez de Castro, J Gallego, ML Limón, M Alsina, L López, M Galán, E Falcó, JL Manzano, E González, N Muñoz-Unceta, C López, E Aranda, E Fernández, M Jorge, P Jiménez-Fonseca

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading